Showing 281-287 of 287 results for "".
- American Academy of Optometry Foundation Announces the 2019 Beta Sigma Kappa (BSK) Research Fellowship Recipienthttps://modernod.com/news/american-academy-of-optometry-foundation-announces-the-2019-beta-sigma-kappa-bsk-research-fellowship-recipient/2476908/The American Academy of Optometry Foundation (AAOF) in collaboration with the Beta Sigma Kappa International Optometric Honor Society, has announced Sima T. Mozdbar, OD, as the 2019 recipient of the Beta Sigma Kappa (BSK) Research Fellowship. Dr. Mozdbar is an Adjunct Clinical Professor at the Un
- BVI Announces Certification for its IOL Portfolio Under the European Medical Device Regulationhttps://modernod.com/news/bvi-announces-certification-for-its-iol-portfolio-under-the-european-medical-device-regulation/2481094/BVI announced certification for its IOL portfolio under the European Medical Device Regulation (MDR, (EU) 2017/745) from its Notified Body, the British Standards Institution (BSI)¹. The new regulatory criteria came into effect in May 2021, replacing the prior Medica
- CooperVision Expands Leadership Teamhttps://modernod.com/news/coopervision-expands-leadership-team/2479259/CooperVision announced the hiring of Kamela Bearlin as Senior Global Brand Director, 1 Day Brands; and Jennifer Lambert as Senior Global Brand Director, Myopia Management; and promoted Elizabeth Lumb, BSc(Hons) MCOptom, FBCLA, to Director of Global Professional Affairs, Myopia Management.
- AstraZeneca’s Calquence Fails to Help Patients Hospitalized With COVID-19 Respiratory Symptomshttps://modernod.com/news/astrazenecas-calquence-fails-to-help-patients-hospitalized-with-covid-19-respiratory-symptoms/2478544/AstraZeneca announced that the phase 2 CALAVI studies investigating the addition of Calquence (acalabrutinib) to best supportive care (BSC) in patients hospitalized with respiratory symptoms of COVID-19 failed to meet their primary efficacy endpoint. Results showed that the BTK inhibitor did not
- Bionic Sight Doses First Patient in a Phase 1/2 Clinical Trial of a New Investigational Treatment for Retinitis Pigmentosahttps://modernod.com/news/bionic-sight-llc-doses-first-patient-in-a-phase-1-2-clinical-trial-of-a-new-investigational-treatment-for-blindness-caused-by-retinitis-pigmentosa/2477902/Bionic Sight announced that it has dosed the first patient in the company’s phase 1/2 clinical trial of BS01, an optogenetic gene therapy for patients with retinitis pigmentosa. This is an important step toward bringing BS01 forward as a treatment to enable patients with retinal degenerative dise
- Easy Anyamahttps://modernod.com/profiles/easy-anyama/7ZB1bk/
- Tracy Offerdahl, BSc, PharmD, FAAOhttps://modernod.com/profiles/tracy-offerdahl-bsc-pharmd-faao/j3ezpR/
- Previous
- Next